Cargando…
The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223077/ https://www.ncbi.nlm.nih.gov/pubmed/30404621 http://dx.doi.org/10.1186/s12957-018-1516-1 |
_version_ | 1783369353977135104 |
---|---|
author | Wang, Yichun Zhu, Liyang Xia, Wanli Wu, Liming Wang, Fan |
author_facet | Wang, Yichun Zhu, Liyang Xia, Wanli Wu, Liming Wang, Fan |
author_sort | Wang, Yichun |
collection | PubMed |
description | BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC with a minimum 2-year follow-up after oesophagectomy were analysed. The survival and recurrence patterns were compared among patients who received adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemoradiotherapy, or surgery alone. RESULTS: Eighty-eight patients (69.3%) were identified as having disease recurrence. The regional lymph node recurrence rate was 57.5%, and the recurrence rates were high in the lower neck, upper mediastinum, and upper abdomen. Compared to surgery alone, adjuvant radiotherapy or chemoradiotherapy significantly decreased the recurrence rate (p < 0.05). Adjuvant chemoradiotherapy significantly improved overall survival, disease-free survival, and locoregional recurrence-free survival compared to surgery alone (p = 0.01, 0.01, and 0.00, respectively). Pathologically positive lymph nodes (PPLNs) in the lower mediastinum represented a potential risk factor for cervical recurrence (HR 2.97, 95%CI 1.19–7.39). Multivariable analysis showed that postoperative radiotherapy (HR 0.30, 95%CI 0.13–0.68) and PPLNs in the upper mediastinum (HR 3.72, 95%CI 1.30–10.67) were independent risk factors for upper mediastinal recurrence, while postoperative radiotherapy (HR 0.37, 95%CI 0.16–0.85) and PPLNs in the abdomen (HR 2.57, 95%CI 1.12–5.92) were independent risk factors for abdominal recurrence. CONCLUSION: Adjuvant chemoradiotherapy was the most effective adjuvant therapy for resected stage IIa-IVa LTESCC. The lower neck, upper mediastinum, and upper abdomen were high-risk regions for postoperative radiotherapy. The regions of PPLNs may be important factors for individual targets. |
format | Online Article Text |
id | pubmed-6223077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62230772018-11-19 The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma Wang, Yichun Zhu, Liyang Xia, Wanli Wu, Liming Wang, Fan World J Surg Oncol Research BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC with a minimum 2-year follow-up after oesophagectomy were analysed. The survival and recurrence patterns were compared among patients who received adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemoradiotherapy, or surgery alone. RESULTS: Eighty-eight patients (69.3%) were identified as having disease recurrence. The regional lymph node recurrence rate was 57.5%, and the recurrence rates were high in the lower neck, upper mediastinum, and upper abdomen. Compared to surgery alone, adjuvant radiotherapy or chemoradiotherapy significantly decreased the recurrence rate (p < 0.05). Adjuvant chemoradiotherapy significantly improved overall survival, disease-free survival, and locoregional recurrence-free survival compared to surgery alone (p = 0.01, 0.01, and 0.00, respectively). Pathologically positive lymph nodes (PPLNs) in the lower mediastinum represented a potential risk factor for cervical recurrence (HR 2.97, 95%CI 1.19–7.39). Multivariable analysis showed that postoperative radiotherapy (HR 0.30, 95%CI 0.13–0.68) and PPLNs in the upper mediastinum (HR 3.72, 95%CI 1.30–10.67) were independent risk factors for upper mediastinal recurrence, while postoperative radiotherapy (HR 0.37, 95%CI 0.16–0.85) and PPLNs in the abdomen (HR 2.57, 95%CI 1.12–5.92) were independent risk factors for abdominal recurrence. CONCLUSION: Adjuvant chemoradiotherapy was the most effective adjuvant therapy for resected stage IIa-IVa LTESCC. The lower neck, upper mediastinum, and upper abdomen were high-risk regions for postoperative radiotherapy. The regions of PPLNs may be important factors for individual targets. BioMed Central 2018-11-07 /pmc/articles/PMC6223077/ /pubmed/30404621 http://dx.doi.org/10.1186/s12957-018-1516-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wang, Yichun Zhu, Liyang Xia, Wanli Wu, Liming Wang, Fan The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title | The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title_full | The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title_fullStr | The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title_full_unstemmed | The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title_short | The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma |
title_sort | impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage iia–iva lower thoracic oesophageal squamous cell carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223077/ https://www.ncbi.nlm.nih.gov/pubmed/30404621 http://dx.doi.org/10.1186/s12957-018-1516-1 |
work_keys_str_mv | AT wangyichun theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT zhuliyang theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT xiawanli theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT wuliming theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT wangfan theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT wangyichun impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT zhuliyang impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT xiawanli impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT wuliming impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma AT wangfan impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma |